|
1
|
Kaprin AD, Kostin AA, Rapoport LM,
Tsarichenko DG, Bernikov AN, Vorob'ev NV and Golovashchenko MP:
Cancer of urinary bladder. Urologiia. 6 Suppl:S64–S88. 2016.(In
Russian).
|
|
2
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmstrom PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder
cancer. Lancet. 388:2796–2810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lan Y, Liu D and Lin M: Comparison of the
combination therapy of bacillus Calmette-Guerin and mitomycin C
with the monotherapy for non-muscle-invasive bladder cancer: A
meta-analysis. Neoplasma. 63:967–976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krasnow RE, Drumm M, Roberts HJ, Niemierko
A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, et al:
Clinical outcomes of patients with histologic variants of
urothelial cancer treated with trimodality bladder-sparing therapy.
Eur Urol. 72:54–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ding XF, Shen M, Xu LY, Dong JH and Chen
G: 13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-β-elemene, a novel
β-elemene derivative, shows potent antitumor activities via
inhibition of mTOR in human breast cancer cells. Oncol Lett.
5:1554–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Z, Wu H, Li Y, Hou Q, Wang Y, Li S, Xia
B and Wu S: β-Elemene inhibits the proliferation of esophageal
squamous cell carcinoma by regulating long noncoding RNA-mediated
inhibition of hTERT expression. Anticancer Drugs. 26:531–539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou S, Wang C, Cui Z, Guo P, Meng Q, Shi
X, Gao Y, Yang G and Han Z: β-Elemene induces apoptosis of human
rheumatoid arthritis fibroblast-like synoviocytes via reactive
oxygen species-dependent activation of p38 mitogen-activated
protein kinase. Pharmacol Rep. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen JC, Duan WL, Bai RR, Yao HQ, Wu XM,
Shang J and Xu JY: Synthesis of 13-β-elemene ester derivatives and
evaluation of their antioxidant activity in human umbilical vein
endothelial cells. Chin J Nat Med. 13:618–627. 2015.PubMed/NCBI
|
|
9
|
Hong L, Zeng Y and Yang D: Inhibitory
effect of β-elemene on human airway granulation tissue in vivo and
in vitro. Respiration. 92:329–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olasz J, Doleschall Z, Dunai Z, Pazsitka A
and Csuka O: PI3K/AKT pathway activation and therapeutic
consequences in breast cancer. Magy Onkol. 59:346–351. 2015.(In
Hungarian). PubMed/NCBI
|
|
12
|
Brotelle T and Bay JO: PI3K-AKT-mTOR
pathway: Description, therapeutic development, resistance,
predictive/prognostic biomarkers and therapeutic applications for
cancer. Bull Cancer. 103:18–29. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rana C, Piplani H, Vaish V, Nehru B and
Sanyal SN: Downregulation of PI3-K/Akt/PTEN pathway and activation
of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in
colon cancer. Mol Cell Biochem. 402:225–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chun SH, Jung CK, Won HS, Kang JH, Kim YS
and Kim MS: Divergence of P53, PTEN, PI3K, Akt and mTOR expression
in tonsillar cancer. Head Neck. 37:636–643. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lim HJ, Crowe P and Yang JL: Current
clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment
of human cancer. J Cancer Res Clin Oncol. 141:671–689. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chin CC, Li JM, Lee KF, Huang YC, Wang KC,
Lai HC, Cheng CC, Kuo YH and Shi CS: Selective β2-AR blockage
suppresses colorectal cancer growth through regulation of
EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis. J Cell
Physiol. 231:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Dai B, Zhang H, Shi G, Shen Y and
Ye D: Long non-coding RNA LOC572558 inhibits bladder cancer cell
proliferation and tumor growth by regulating the AKT-MDM2-p53
signaling axis. Cancer Lett. 380:369–374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Wang T, Xu S, Zhang P, Lin A, Wu
L, Yao H, Xie W, Zhu Z and Xu J: Discovery of novel antitumor
nitric oxide-donating β-elemene hybrids through inhibiting the
PI3K/Akt pathway. Eur J Med Chem. 135:414–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu X, Xu M, Li N, Li Z, Li H, Shao S, Zou
K and Zou L: β-elemene inhibits tumor-promoting effect of M2
macrophages in lung cancer. Biochem Biophys Res Commun.
490:514–520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mu L, Wang T, Chen Y, Tang X, Yuan Y and
Zhao Y: β-Elemene enhances the efficacy of gefitinib on
glioblastoma multiforme cells through the inhibition of the EGFR
signaling pathway. Int J Oncol. 49:1427–1436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Zhang HD, Yao YF, Zhong SL, Zhao
JH and Tang JH: β-elemene reverses chemoresistance of breast cancer
cells by reducing resistance transmission via exosomes. Cell
Physiol Biochem. 36:2274–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Wang R, Wang T, Ding Q, Khalil A,
Xu S, Lin A, Yao H, Xie W, Zhu Z and Xu J: Antioxidant properties
of novel dimers derived from natural β-elemene through inhibiting
H2O2-induced apoptosis. ACS Med Chem Lett.
8:443–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma C, Zhou W, Yan Z, Qu M and Bu X:
β-Elemene treatment of glioblastoma: A single-center retrospective
study. Onco Targets Ther. 9:7521–7526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Wang Y, Luo H, Luo Z, Zhang T,
Yang N, Long X, Xie H, Qiu W, Zhang B, Ding J and Yang L: β-elemene
acts as an antitumor factor and downregulates the expression of
survivin, Bcl-xL and Mta-1. Mol Med Rep. 6:989–995. 2012.PubMed/NCBI
|
|
25
|
Lu X, Wang Y, Luo H, Qiu W, Han H and Chen
X: β-elemene inhibits the proliferation of T24 bladder carcinoma
cells through upregulation of the expression of Smad4. Mol Med Rep.
7:513–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanaka M and Grossman HB: In vivo gene
therapy of human bladder cancer with PTEN suppresses tumor growth,
downregulates phosphorylated Akt, and increases sensitivity to
doxorubicin. Gene Ther. 10:1636–1642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin C, Tsai SC, Tseng MT, Peng SF, Kuo SC,
Lin MW, Hsu YM, Lee MR, Amagaya S, Huang WW, et al: AKT
serine/threonine protein kinase modulates baicalin-triggered
autophagy in human bladder cancer T24 cells. Int J Oncol.
42:993–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao B and Li X: Altholactone induces
reactive oxygen species-mediated apoptosis in bladder cancer T24
cells through mitochondrial dysfunction, MAPK-p38 activation and
Akt suppression. Oncol Rep. 31:2769–2775. 2014. View Article : Google Scholar : PubMed/NCBI
|
